In recent years, a number of preclinical models have shown that cannabinoids may be highly effective at improving inflammation and, therefore, may be a potential treatment for inflammatory bowel diseases.
Although they are less likely to receive it, patients hospitalized with inflammatory bowel disease should be placed on venous thromboembolism prophylaxis to reduce the number of preventable VTE events.
To better understand the real-world prescribing patterns of certolizumab, researchers collected data from a large multicenter gastroenterology private practice dating back to 2008.
Treatment with ontamalimab was associated with both clinical and symptomatic remission in patients with ulcerative colitis (UC), according to data presented at the 2019 AIBD Annual Meeting held in Orlando, Florida.
Inflammatory bowel disease (IBD) diagnosis appears to be associated with high levels of anxiety and depression in children, however, new study findings presented at the 2019 AIBD Annual Meeting suggest that many of these patients may not be receiving appropriate mental health services.
Trends in the utilization of emergency department (ED) care and hospitalization among patients with inflammatory bowel disease (IBD) were investigated in a new study.
The safety profiles of various IV iron products were compared in a study involving patients with inflammatory bowel disease IBD being treated for iron deficiency anemia.
Treatment with adalimumab or infliximab in biologic-naive patients with Crohn disease or ulcerative colitis demonstrated similar outcomes on Patient-Reported Outcomes Measurement Information System measures and rates of corticosteroid-free remission.
“The data indicate that more conservative periodontal therapy might initially be considered for IBD patients with advanced periodontal disease for whom PPI are prescribed as a component of their IBD treatment,” the authors concluded.
According to new research over 1 in 5 patients with inflammatory bowel disease (IBD) should have started treatment with an advanced systemic therapy earlier in their disease.
Combination biologic therapy may be an effective treatment option for patients with inflammatory bowel disease (IBD) who are refractory or have a concomitant autoimmune disease that is inadequately controlled by biologic monotherapy.
Biosimilar BI 695501 demonstrated non-inferior efficacy and similar safety profile compared with the reference product adalimumab in patients with active Crohn disease.
Vedolizumab demonstrated long-term effectiveness and favorable safety profile in patients with moderately-to-severely active ulcerative colitis and Crohn Disease.
Proactive monitoring of adalimumab trough concentrations in children was associated with higher corticosteroid-free sustained remission and biologic remission rates compared with reactive monitoring in pediatric patients with Crohn disease.
IBD clinical trials have become increasingly complex as more specific clinical endpoints have gathered support within the academic arena. There has also been an emphasis on long-term extension safety and efficacy data which can further complicate recruitment.
The abundance of particular gut microbes believed to regulate immune response were reduced in fecal samples from participants on the low-FODMAP diet compared with those on the control diet.
